<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo2385" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38770399</article-id><article-id pub-id-type="pmc">PMC11103454</article-id>
<article-id pub-id-type="doi">10.1002/deo2.385</article-id><article-id pub-id-type="publisher-id">DEO2385</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Is annual screening by fecal immunochemical test necessary after a recent colonoscopy?</article-title><alt-title alt-title-type="left-running-head">OKAGAWA <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo2385-cr-0001" contrib-type="author" corresp="yes"><name><surname>Okagawa</surname><given-names>Yutaka</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1215-1901</contrib-id><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>yutaka.okagawa@tonan.gr.jp</email></address></contrib><contrib id="deo2385-cr-0002" contrib-type="author"><name><surname>Sumiyoshi</surname><given-names>Tetsuya</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9390-8477</contrib-id><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0003" contrib-type="author"><name><surname>Hanada</surname><given-names>Kota</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0004" contrib-type="author"><name><surname>Hirokawa</surname><given-names>Sota</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0005" contrib-type="author"><name><surname>Tomita</surname><given-names>Yusuke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2746-8020</contrib-id><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0006" contrib-type="author"><name><surname>Yoshida</surname><given-names>Masahiro</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0007" contrib-type="author"><name><surname>Minagawa</surname><given-names>Takeyoshi</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0008" contrib-type="author"><name><surname>Morita</surname><given-names>Kohtaro</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0009" contrib-type="author"><name><surname>Yane</surname><given-names>Kei</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4695-5609</contrib-id><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0010" contrib-type="author"><name><surname>Ihara</surname><given-names>Hideyuki</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0011" contrib-type="author"><name><surname>Hirayama</surname><given-names>Michiaki</given-names></name><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2385-cr-0012" contrib-type="author"><name><surname>Kondo</surname><given-names>Hitoshi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3905-030X</contrib-id><xref rid="deo2385-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo2385-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Tonan Hospital</institution>
<named-content content-type="country-part">Hokkaido</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Yutaka Okagawa, Department of Gastroenterology, Tonan Hospital, North 4, West 7, Chuo&#x02010;ku, Sapporo, Hokkaido 060&#x02010;0004, Japan.<break/> Email: <email>yutaka.okagawa@tonan.gr.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="131">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e385</elocation-id><history>
<date date-type="rev-recd"><day>22</day><month>4</month><year>2024</year></date>
<date date-type="received"><day>08</day><month>3</month><year>2024</year></date>
<date date-type="accepted"><day>29</day><month>4</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Authors. <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e385.pdf"/><abstract><title>Abstract</title><sec id="deo2385-sec-0010"><title>Objective</title><p>The population&#x02010;based colorectal cancer screening guidelines in Japan recommend an annual fecal immunochemical test (FIT). However, there is no consensus on the need for annual FIT screening for patients who recently performed a total colonoscopy (TCS). Therefore, we evaluated the repeated TCS results for patients with positive FIT after a recent TCS to assess the necessity of an annual FIT.</p></sec><sec id="deo2385-sec-0020"><title>Methods</title><p>We reviewed patients with positive FIT in opportunistic screening from April 2017 to March 2022. The patients were divided into two groups: those who had undergone TCS within the previous 5 years (previous TCS group) and those who had not (non&#x02010;previous TCS group). We compared the detection rates of advanced neoplasia and colorectal cancer between the two groups.</p></sec><sec id="deo2385-sec-0030"><title>Results</title><p>Of 671 patients, 151 had received TCS within 5 years and 520 had not. The detection rates of advanced neoplasia in the previous TCS and non&#x02010;previous TCS groups were 4.6% and 12.1%, respectively (<italic toggle="yes">p</italic> &#x0003c; 0.01), and the colorectal cancer detection rates were 0.7% and 1.5%, respectively (no significant difference). The adenoma detection rates were 33.8% in the previous TCS group and 40.0% in the non&#x02010;previous TCS group (no significant difference).</p></sec><sec id="deo2385-sec-0040"><title>Conclusions</title><p>Only a few patients were diagnosed with advanced neoplasia among the patients with FIT positive after a recent TCS. For patients with adenomatous lesions on previous TCS, repeated TCS should be performed according to the surveillance program without an annual FIT. The need for an annual FIT for patients without adenomatous lesions on previous TCS should be prospectively assessed in the future.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo2385-kwd-0001">advanced neoplasia</kwd><kwd id="deo2385-kwd-0002">colon adenoma</kwd><kwd id="deo2385-kwd-0003">fecal immunochemical test</kwd><kwd id="deo2385-kwd-0004">screening</kwd><kwd id="deo2385-kwd-0005">total colonoscopy</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="6"/><word-count count="3821"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo2385-sec-0050"><title>INTRODUCTION</title><p>Colorectal cancer (CRC) is the second leading cause of cancer&#x02010;related death worldwide, and its incidence is increasing.<xref rid="deo2385-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> In Japan, the prevalence and mortality rates of CRC are also high.<xref rid="deo2385-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Guaiac&#x02010;based fecal occult blood screening reportedly is associated with reduced incidences and mortality of CRC.<xref rid="deo2385-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo2385-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo2385-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Several studies have also shown the effectiveness of fecal immunochemical test (FIT) for CRC.<xref rid="deo2385-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo2385-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Chiu et&#x000a0;al. reported that a single FIT reduced CRC mortality by 62%.<xref rid="deo2385-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> The 2&#x02010;day FIT method is used to perform population&#x02010;based CRC screening in Japan.<xref rid="deo2385-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> If the FIT is positive on even 1 day, further examination, including total colonoscopy (TCS) or computed tomographic colonography, is warranted. Currently, TCS is the main procedure in real&#x02010;world clinical practice in Japan. Several studies have shown that endoscopic removal of adenomatous polyps prevents the development of CRC and reduces CRC&#x02010;related death.<xref rid="deo2385-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo2385-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Although TCS is useful for direct observation of the colorectal mucosa, the risk of post&#x02010;colonoscopy CRC remains because TCS can miss some lesions. Reportedly, half of post&#x02010;colonoscopy CRCs have been diagnosed after colorectal lesions had been missed.<xref rid="deo2385-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> The Japanese guidelines recommend appropriate TCS intervals depending on the results of the previous TCS.<xref rid="deo2385-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> As mentioned above, the population&#x02010;based CRC screening guidelines in Japan recommend an annual FIT.<xref rid="deo2385-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Therefore, we often experience cases in which FIT results are positive in an opportunistic screening within a few years of the individual having undergone a TCS. Currently, there is insufficient data supporting the benefit of repeated TCS for patients with positive FIT results after a recent TCS, and there is no consensus on the need for annual FIT screening. This study aimed to retrospectively evaluate the results of repeated TCS for patients with positive FIT results after a recent colonoscopy and assess the necessity of an annual FIT for such cases.</p></sec><sec id="deo2385-sec-0060"><title>METHODS</title><sec id="deo2385-sec-0070"><title>Study design</title><p>This was a single&#x02010;center, retrospective cohort study. The study protocol was approved by the Institutional Review Board of Tonan Hospital (approved number 1&#x02010;15&#x02010;1) and was conducted in compliance with the principles of the Declaration of Helsinki. Although written informed consent was not obtained from the patients because of the study design, all participants were informed that they could opt out on the hospital's website.</p></sec><sec id="deo2385-sec-0080"><title>Patients</title><p>This study included consecutive patients whose FIT was positive for opportunistic screening at the health screening center of Tonan Hospital in Japan from April 2017 to March 2022. The cutoff value of FIT positivity in our hospital is 100 ng/mL. The inclusion criteria were asymptomatic patients aged &#x02265;40 years whose FIT was positive even if only on 1 day. The exclusion criteria were patients with a history of colectomy for CRC, inflammatory bowel diseases (IBDs), unknown history of TCS within 5 years, TCS intervals of &#x0003c;6 months, and who had not received TCS after positive FIT results or had received TCS at another hospital with unknown details. The patients were divided into two groups: patients who had received TCS within the past 5 years (previous TCS group) and those who had not (non&#x02010;previous TCS group). In the previous TCS group, for patients who had undergone a total of &#x02265;2 TCS within 5 years, we used the results of the TCS at the first positive FIT results after the initial TCS. The non&#x02010;previous TCS group included patients who had undergone TCS &#x0003e;5 years earlier and patients who had not so far.</p></sec><sec id="deo2385-sec-0090"><title>Endoscopic procedures</title><p>A total of 17 endoscopists used a high&#x02010;resolution colonoscope (CF&#x02010;H260AZI, CF&#x02010;H290I, CF&#x02010;HQ290Z, or PCF&#x02010;H290ZI; [Olympus Medical Systems], EC&#x02010;590ZW/L, and EC&#x02010;600ZW/L [Fujifilm]) with carbon dioxide insufflation to perform the colonoscopies. A polyethylene glycol electrolyte solution containing ascorbic acid (MoviPrep; Ajinomoto) and magnesium citrate (Magcorol P; Horii Pharmaceutical) was used to empty and prepare the bowels. Conscious sedation using intravenous administration of diazepam or midazolam and pentazocine was administered during the examination, as required.</p></sec><sec id="deo2385-sec-0100"><title>Outcome measures</title><p>We analyzed the medical records and endoscopic images of the patients, including the patients&#x02019; backgrounds, comorbidities, use of antithrombotic agents, years from previous TCS, reasons for previous TCS, previous TCS results, and detected polyps results. According to a previous report,<xref rid="deo2385-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> the definition of advanced neoplasia (AN) in this study was advanced adenoma (a tubular adenoma &#x02265;10 mm in size, with a villous histology, or high&#x02010;grade dysplasia) or invasive cancer. The principal study outcome was the detection rate of AN and invasive cancer in patients who underwent colonoscopy within 5 years. The secondary outcome was the adenoma detection rate (ADR).</p></sec><sec id="deo2385-sec-0110"><title>Statistical analysis</title><p>EZR (Saitama Medical Center, Jichi Medical University), a graphical user interface for R v.2.13.0 (R Foundation for Statistical Computing) was used to perform all statistical analyses.<xref rid="deo2385-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Quantitative variables are expressed as the median, whereas categorical variables are presented as total numbers and percentages. Pearson's chi&#x02010;square test and the Mann&#x02013;Whitney U&#x02010;test were performed as appropriate. Values of <italic toggle="yes">p</italic> &#x0003c; 0.05 were accepted as indicating statistical significance.</p></sec></sec><sec id="deo2385-sec-0120"><title>RESULTS</title><sec id="deo2385-sec-0130"><title>Patients&#x02019; characteristics</title><p>Overall, 24,150 individuals underwent FIT for opportunistic screening at our hospital from April 2017 to March 2022. Of these, 1354 were patients with FIT positive with a positive rate of 5.6% in the screening population. On a patient basis, a total of 1193 patients had &#x02265;1 positive FIT. Of these patients, 522 were excluded for the following reasons: patients aged &#x0003c; 40 (<italic toggle="yes">n</italic> = 70), patients with a past colectomy for CRC (<italic toggle="yes">n</italic> = 5), patients with inflammatory bowel diseases (<italic toggle="yes">n</italic> = 3), and patients who had not received TCS or had received TCS at another hospital with unknown details (<italic toggle="yes">n</italic> = 444). Finally, we analyzed 671 patients (Figure&#x000a0;<xref rid="deo2385-fig-0001" ref-type="fig">1</xref>). The baseline patient characteristics are presented in Table&#x000a0;<xref rid="deo2385-tbl-0001" ref-type="table">1</xref>. A total of 151 patients had undergone TCS within 5 years, and 520 had not. In the non&#x02010;previous TCS group, 37 patients had undergone TCS &#x0003e;5 years ago. The median age was 59 years in the previous TCS group and 55 years in the non&#x02010;previous TCS group, which was a significant difference (<italic toggle="yes">p</italic> &#x0003c; 0.01). The proportion of males was not significantly different between the two groups (<italic toggle="yes">p</italic> = 0.44). There were significant differences in the presence of dyslipidemia (<italic toggle="yes">p</italic> = 0.02) and the medical history of malignancy, excluding CRC (<italic toggle="yes">p</italic> &#x0003c; 0.01). The administration of antithrombotic agents was significantly different between the two groups (<italic toggle="yes">p</italic> = 0.04). In the previous TCS group, 101 patients had received TCS within 3 years and 50 had received TCS within 3&#x02013;5 years. A positive FIT result was the most common reason for performing previous TCS (62.3%). In the previous TCS, insertion to the cecum was achieved in all patients and all adenomatous lesions were resected. The previous TCS results showed that 104 patients had no adenomatous lesions, 40 had adenomatous lesions excluding AN, and seven had AN.</p><fig position="float" fig-type="FIGURE" id="deo2385-fig-0001"><label>FIGURE 1</label><caption><p>Patient selection flow diagram for the study.</p><p>Abbreviations: CRC, colorectal cancer; FIT, fecal immunochemical test; IBD, inflammatory bowel disease; TCS, total colonoscopy.</p></caption><graphic xlink:href="DEO2-5-e385-g001" position="anchor" id="jats-graphic-1"/></fig><table-wrap position="float" id="deo2385-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patients&#x02019; characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Previous TCS</th><th align="left" rowspan="1" colspan="1">Non&#x02010;previous TCS</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 151</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 520</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age, years (range)</td><td align="left" rowspan="1" colspan="1">59 (41&#x02013;82)</td><td align="left" rowspan="1" colspan="1">55 (40&#x02013;86)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Male/female</td><td align="left" rowspan="1" colspan="1">108/43</td><td align="left" rowspan="1" colspan="1">350/170</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity</td><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="char" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">98</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia</td><td align="char" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">46</td><td align="char" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td><td align="char" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1">Past history of malignancy (exc CRC)</td><td align="char" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">25</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Antithrombotic agents</td><td align="char" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">18</td><td align="char" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Years from previous TCS</td><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;3 years</td><td align="char" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3&#x02013;5 years</td><td align="char" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Reasons for previous TCS</td><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive FIT</td><td align="char" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Screening</td><td align="char" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Surveillance</td><td align="char" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Others</td><td align="char" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Results of previous TCS</td><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No adenomatous lesion</td><td align="char" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adenoma (excluding AN)</td><td align="char" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">AN</td><td align="char" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo2385-tbl1-note-0001"><p>Abbreviations: AN, advanced neoplasia; CRC, colorectal cancer; FIT, fecal immunochemical test; TCS, total colonoscopy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo2385-sec-0140"><title>Findings of TCS after a positive FIT result</title><p>On TCS after a positive FIT result, the detection rate of AN was 4.6% in the previous TCS group (Table&#x000a0;<xref rid="deo2385-tbl-0002" ref-type="table">2</xref>), which included one (0.7%) patient with invasive cancer and six patients with advanced adenomas. The patients with invasive cancer had undergone TCS 1 year earlier, and the current TCS showed a laterally spreading tumor (non&#x02010;granular type) in the hepatic flexure of the transverse colon, revealing a T1b cancer. The ADR in the previous TCS group was 33.8%. On the other hand, the detection rate of AN was 12.1% in the non&#x02010;previous TCS group, which was significantly higher than that in the previous TCS group (<italic toggle="yes">p</italic> &#x0003c; 0.01). The CRC detection rate was 1.5% in the non&#x02010;previous TCS group. The ADR of the non&#x02010;previous TCS group was 40.0%, which was not significantly different from that of the previous TCS group. In the previous TCS group, 102 adenomas or CRCs were detected. The sigmoid colon was the most common location of detected polyps. The same trend was observed in the non&#x02010;previous TCS group (Table&#x000a0;<xref rid="deo2385-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="deo2385-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Detection rates of adenoma and advanced neoplasia.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Previous TCS</th><th align="left" rowspan="1" colspan="1">Non&#x02010;previous TCS</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 151</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 520</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Adenoma detection rate</td><td align="char" rowspan="1" colspan="1">33.8%</td><td align="char" rowspan="1" colspan="1">40.0%</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1">AN detection rate</td><td align="char" rowspan="1" colspan="1">4.6%</td><td align="char" rowspan="1" colspan="1">12.1%</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Invasive cancer detection rate</td><td align="char" rowspan="1" colspan="1">0.7%</td><td align="char" rowspan="1" colspan="1">1.5%</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr></tbody></table><table-wrap-foot><fn id="deo2385-tbl2-note-0001"><p>Abbreviations: AN, advanced neoplasia; TCS, total colonoscopy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo2385-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Location of detected lesions.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Detected adenoma or CRC (%)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Location</th><th align="left" rowspan="1" colspan="1">Previous TCS</th><th align="left" rowspan="1" colspan="1">Non&#x02010;previous TCS</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cecum</td><td align="char" rowspan="1" colspan="1">6 (5.9)</td><td align="char" rowspan="1" colspan="1">38 (8.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ascending colon</td><td align="char" rowspan="1" colspan="1">23 (22.5)</td><td align="char" rowspan="1" colspan="1">72 (15.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Transverse colon</td><td align="char" rowspan="1" colspan="1">21 (20.6)</td><td align="char" rowspan="1" colspan="1">89 (19.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Descending colon</td><td align="char" rowspan="1" colspan="1">13 (12.7)</td><td align="char" rowspan="1" colspan="1">59 (13.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sigmoid colon</td><td align="char" rowspan="1" colspan="1">29 (28.4)</td><td align="char" rowspan="1" colspan="1">137 (30.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">10 (9.8)</td><td align="char" rowspan="1" colspan="1">57 (12.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="char" rowspan="1" colspan="1">102 (100)</td><td align="char" rowspan="1" colspan="1">452 (100)</td></tr></tbody></table><table-wrap-foot><fn id="deo2385-tbl3-note-0001"><p>Abbreviations: CRC, colorectal cancer; TCS, total colonoscopy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In the 101 patients who had received TCS within 3 years, the ADR and detection rate of AN were 35.6% and 5.0%, respectively, which were not significantly different from the rates of the patients who had received TCS within 3&#x02013;5 years (ADR: 30.6%, AN: 4.0%). In the previous TCS group, AN was found in the previous TCS in seven patients. The AN detection rate and ADR in repeat TCS for these patients were 14.3% and 100%, respectively. The rates in patients with adenomas excluding AN in the previous TCS group were 7.5% and 50%, respectively. The rates in patients with no adenomatous lesions in the previous TCS group were 2.8% and 19.2%, respectively (Table&#x000a0;<xref rid="deo2385-tbl-0004" ref-type="table">4</xref>). The ADR was significantly higher in patients with previous AN than in patients with previous adenoma (excluding AN; <italic toggle="yes">p</italic> &#x0003c; 0.05). Furthermore, the ADR was significantly higher in patients with previous adenoma (excluding AN) than in patients with no previous adenoma (<italic toggle="yes">p</italic> &#x0003c; 0.01). The ADR and AN detection rates were significantly higher in patients with &#x02265;3 adenomatous lesions in the previous TCS than in those without adenomatous lesions. Patients with 1&#x02013;2 adenomatous lesions in the previous TCS also had higher ADR than those without in the previous TCS (Table <xref rid="deo2385-supitem-0001" ref-type="supplementary-material">S1</xref>). Furthermore, when the adenomatous lesions in the previous TCS were divided by size, patients with lesions &#x02265;10 mm had a significantly higher ADR than those with lesions &#x0003c;10 mm or without adenomatous lesions (Table <xref rid="deo2385-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><table-wrap position="float" id="deo2385-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Comparison of detection rates based on previous total colonoscopy results.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="DEO2-5-e385-g002.jpg" xlink:title="image"/>
</td></tr></tbody></table><table-wrap-foot><fn id="deo2385-tbl4-note-0001"><p>Abbreviations: AN, advanced neoplasia; TCS, total colonoscopy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="deo2385-sec-0150"><title>DISCUSSION</title><p>The population&#x02010;based CRC screening guidelines in Japan recommend the annual 2&#x02010;day FIT method<xref rid="deo2385-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>; therefore, there are often patients with positive FIT results, so detailed examination is required despite having undergone TCS within a few years. Due to the high efficacy of FIT, the US Multi&#x02010;Society Task Force recommends that patients with positive FIT results should be offered a repeated colonoscopy even if a recent colonoscopy was performed, considering the patient background and quality of the previous TCS.<xref rid="deo2385-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> However, this is a weak recommendation based on expert opinion and low&#x02010;quality evidence, and there is limited data to inform clinicians on the optimal approach for treating patients with positive FIT results and recent colonoscopies.</p><p>In the present study, patients in the previous TCS group were significantly older. This was not surprising, as performing previous TCS was generally thought to be more common in older patients. The significant difference in medical history or administration of antithrombotic agents may have been influenced by differences in age. We analyzed TCS results after positive FIT results in patients who had undergone TCS within 5 years, the detection rate of AN was 4.6%, and the detection rate of CRC was 0.7%. Several studies have reported the association between repeat colonoscopy for patients with positive FIT results and recent colonoscopy.<xref rid="deo2385-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo2385-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="deo2385-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo2385-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo2385-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Kim et&#x000a0;al. reported the results of TCS for patients aged &#x02265;50 years with positive FIT results.<xref rid="deo2385-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> They found that the detection rates of AN and CRC were 10.9% and 2.1%, respectively, despite having performed TCS within 3 years. Therefore, they suggested repeat colonoscopy for patients with a positive FIT result and a recent TCS, as recommended by the U.S. Multi&#x02010;Society Task Force. Another study group also analyzed patients aged &#x02265;50 years with a positive FIT result and a recent TCS and reported that the AN detection rate was 10.3% among those who underwent TCS within 4 years.<xref rid="deo2385-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> They concluded that TCS within 4 years was protective against CRC because CRC was not found in those patients. Kawamura et&#x000a0;al. reported the results of patients aged &#x02265;40 years, and the AN and CRC detection rates were 3.9% and 0.3%, respectively, in patients who had undergone TCS within 5 years.<xref rid="deo2385-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> These results are consistent with our own. Furthermore, the researchers suggested that rescreening with a FIT should not be recommended for &#x02264;5 years for average&#x02010;risk patients because of the low risk of CRC. On the other hand, Peng et&#x000a0;al. reported TCS results for patients with positive FIT results and recent negative TCS findings.<xref rid="deo2385-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> They showed that the CRC incidence per 1000 persons years was 1.34 in patients who had received a subsequent FIT and 2.69 in those who had not, with a corresponding hazard ratio of 0.47. They concluded that a subsequent FIT should be scheduled after negative TCS findings. Whether or not an annual FIT should be administered after TCS remains controversial. Currently, an annual FIT is recommended, and when an FIT result is positive after a TCS, a repeat TCS must be performed. However, if the average detection rates of AN and CRC are as low as our results or those of Kawamura, there would be little benefit in performing an annual FIT after TCS.</p><p>In the current study, there was no significant difference in the detection rates of AN between patients who had undergone TCS within 3 years and those who had undergone TCS within 3&#x02013;5 years. The detected AN might be a missed lesion or a rapidly developing lesion.<xref rid="deo2385-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Because of the relatively short period of 5 years, the detected ANs will probably be missed lesions rather than rapidly developing lesions. Therefore, we assume that there was no difference in the AN detection rate even when the time periods were separated. Previous reports suggest that TCS should be repeated when there is concern about the quality of the previous TCS or in high&#x02010;risk patients, such as older age or family history of CRC.<xref rid="deo2385-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> In our study, the results of a previous TCS affected those of a TCS after a positive FIT result, and patients with previous AN, &#x02265;3 adenomatous lesions, and size &#x02265;10 mm showed higher ADR and AN detection rates in TCS after FIT. Reportedly, the results of a previous TCS can affect the results of surveillance TCS.<xref rid="deo2385-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Considering these results, an annual FIT is not warranted in patients with adenoma, especially AN, and TCS at intervals in accordance with colonoscopy screening and surveillance guidelines<xref rid="deo2385-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> is preferred. In addition, in patients with no adenoma on the previous TCS, some invasive cancers or ANs were detected on repeated TCS after positive FIT results. Therefore, in the future, it would be necessary to verify the usefulness of FIT in patients with no adenoma detected on the previous TCS.</p><p>There were several limitations in this study that should be considered when interpreting the results. First, this was a single&#x02010;center retrospective study; therefore, we could not conduct detailed investigations of the patients&#x02019; backgrounds, such as family history of CRC. Furthermore, we could not evaluate the quality indicators of TCS, such as bowel preparation quality and ADR of each endoscopist. Second, this was not a population&#x02010;based study, so there was some degree of selection bias. Therefore, this study could not be stratified by risk of patient background or previous TCS results. Furthermore, approximately 37% of patients with FIT positive were excluded because they had not received TCS or had received TCS at another hospital and had incomplete information. This study suffered from a severe selection bias. Third, the number of patients in this study was small. Fourth, adenomatous lesions, but not serrated lesions, were examined in this study. Finally, because this was not a prospective study, we were unable to specify whether or not an annual FIT after the recent TCS was necessary.</p><p>In conclusion, although some patients were diagnosed with AN or invasive cancer among the patients with FIT&#x02010;positive results and who had undergone TCS within 5 years, the detection rate was low, which suggests that an annual FIT after TCS is unnecessary. Repeated TCS should be performed at intervals according to current guidelines without an annual FIT, particularly in patients with adenomatous lesions on previous TCS. In the future, the necessity of an annual FIT for patients with no adenomatous lesion found in a previous TCS should be assessed in light of our findings. Multicenter prospective studies are warranted to address this issue.</p></sec><sec sec-type="COI-statement" id="deo2385-sec-0160"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo2385-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>TABLE S1</bold> Comparison of detection rates based on the number of adenomas in the previous TCS.</p><p>Abbreviations: TCS, total colonoscopy; AN, advanced neoplasia</p><p>
<bold>TABLE S2</bold> Comparison of detection rates based on the size of adenomas in the previous TCS.</p><p>Abbreviations: TCS, total colonoscopy; AN, advanced neoplasia</p></caption><media xlink:href="DEO2-5-e385-s001.docx"/></supplementary-material></sec></body><back><ref-list id="deo2385-bibl-0001"><title>REFERENCES</title><ref id="deo2385-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo2385-cit-0001">
<string-name>
<surname>Sung</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Siegel</surname>
<given-names>RL</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>
<year>2021</year>; <volume>71</volume>: <fpage>209</fpage>&#x02013;<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo2385-cit-0002">
<string-name>
<surname>Katanoda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hori</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>E</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Updated trends in cancer in Japan: Incidence in 1985&#x02013;2015 and mortality in 1958&#x02010;2018&#x02013;A sign of decrease in cancer incidence</article-title>. <source>J Epidemiol</source>
<year>2021</year>; <volume>31</volume>: <fpage>426</fpage>&#x02013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">33551387</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo2385-cit-0003">
<string-name>
<surname>Mandel</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Church</surname>
<given-names>TR</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study</article-title>. <source>N Engl J Med</source>
<year>1993</year>; <volume>328</volume>: <fpage>1365</fpage>&#x02013;<lpage>1371</lpage>.<pub-id pub-id-type="pmid">8474513</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo2385-cit-0004">
<string-name>
<surname>Hardcastle</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Chamberlain</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>MH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Randomised controlled trial of faecal&#x02010;occult&#x02010;blood screening for colorectal cancer</article-title>. <source>Lancet</source>
<year>1996</year>; <volume>348</volume>: <fpage>1472</fpage>&#x02013;<lpage>1477</lpage>.<pub-id pub-id-type="pmid">8942775</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo2385-cit-0005">
<string-name>
<surname>Faivre</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dancourt</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lejeune</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study</article-title>. <source>Gastroenterology</source>
<year>2004</year>; <volume>126</volume>: <fpage>1674</fpage>&#x02013;<lpage>1680</lpage>.<pub-id pub-id-type="pmid">15188160</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo2385-cit-0006">Giorgi Rossi P, <string-name>
<surname>Vicentini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sacchettini</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Impact of screening program on incidence of colorectal cancer: A cohort study in Italy</article-title>. <source>Am J Gastroenterol</source>
<year>2015</year>; <volume>110</volume>: <fpage>1359</fpage>&#x02013;<lpage>1366</lpage>.<pub-id pub-id-type="pmid">26303133</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo2385-cit-0007">
<string-name>
<surname>Chiu</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Yen</surname>
<given-names>AM</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program</article-title>. <source>Cancer</source>
<year>2015</year>; <volume>121</volume>: <fpage>3221</fpage>&#x02013;<lpage>3229</lpage>.<pub-id pub-id-type="pmid">25995082</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="deo2385-cit-0008">
<collab collab-type="authors">Ministry of Health, Labour and Welfare</collab>
<article-title>. Comprehensive survey of living conditions</article-title>. Accessed 23 September 2023 <ext-link xlink:href="https://www.mhlw.go.jp/english/database/db-hss/cslc-index.html" ext-link-type="uri">https://www.mhlw.go.jp/english/database/db&#x02010;hss/cslc&#x02010;index.html</ext-link>
</mixed-citation></ref><ref id="deo2385-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo2385-cit-0009">
<string-name>
<surname>Winawer</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Zauber</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>MN</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup</article-title>. <source>N Engl J Med</source>
<year>1993</year>; <volume>329</volume>: <fpage>1977</fpage>&#x02013;<lpage>1981</lpage>.<pub-id pub-id-type="pmid">8247072</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo2385-cit-0010">
<string-name>
<surname>Zauber</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Winawer</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>MJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Colonoscopic polypectomy and long&#x02010;term prevention of colorectal&#x02010;cancer deaths</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>366</volume>: <fpage>687</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">22356322</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo2385-cit-0011">
<string-name>
<surname>Robertson</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lieberman</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Winawer</surname>
<given-names>SJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Colorectal cancers soon after colonoscopy: A pooled multicohort analysis</article-title>. <source>Gut</source>
<year>2014</year>; <volume>63</volume>: <fpage>949</fpage>&#x02013;<lpage>956</lpage>.<pub-id pub-id-type="pmid">23793224</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo2385-cit-0012">
<string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kawamura</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Colonoscopy screening and surveillance guidelines</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>486</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">33713493</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo2385-cit-0013">
<string-name>
<surname>Regula</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rupinski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kraszewska</surname>
<given-names>E</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Colonoscopy in colorectal&#x02010;cancer screening for detection of advanced neoplasia</article-title>. <source>N Engl J Med</source>
<year>2006</year>; <volume>355</volume>: <fpage>1863</fpage>&#x02013;<lpage>1872</lpage>.<pub-id pub-id-type="pmid">17079760</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo2385-cit-0014">
<string-name>
<surname>Kanda</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Investigation of the freely available easy&#x02010;to&#x02010;use software &#x02018;EZR&#x02019; for medical statistics</article-title>. <source>Bone Marrow Transplant</source>
<year>2013</year>; <volume>48</volume>: <fpage>452</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">23208313</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo2385-cit-0015">
<string-name>
<surname>Robertson</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Boland</surname>
<given-names>CR</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: A consensus statement by the US Multi&#x02010;Society Task Force on colorectal cancer</article-title>. <source>Gastroenterology</source>
<year>2017</year>; <volume>152</volume>: 1217&#x02013;37.e3.</mixed-citation></ref><ref id="deo2385-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo2385-cit-0016">
<string-name>
<surname>Kim</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>JW</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Yield of repeat colonoscopy in asymptomatic individuals with a positive fecal immunochemical test and recent colonoscopy</article-title>. <source>Gastrointest Endosc</source>
<year>2019</year>; <volume>89</volume>: <fpage>1037</fpage>&#x02013;<lpage>1043</lpage>.<pub-id pub-id-type="pmid">30684602</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo2385-cit-0017">
<string-name>
<surname>Rattan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Willmann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Aston</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>To scope or not &#x02010; the challenges of managing patients with positive fecal occult blood test after recent colonoscopy</article-title>. <source>World J Gastrointest Oncol</source>
<year>2022</year>; <volume>14</volume>: <fpage>1798</fpage>&#x02013;<lpage>1807</lpage>.<pub-id pub-id-type="pmid">36187395</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo2385-cit-0018">
<string-name>
<surname>Kawamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sone</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Risk of colorectal cancer for fecal immunochemistry test&#x02010;positive, average&#x02010;risk patients after a colonoscopy</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2019</year>; <volume>34</volume>: <fpage>532</fpage>&#x02013;<lpage>536</lpage>.<pub-id pub-id-type="pmid">30357912</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo2385-cit-0019">
<string-name>
<surname>Peng</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>WF</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>YW</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population&#x02010;based screening programme</article-title>. <source>Gut</source>
<year>2021</year>; <volume>70</volume>: <fpage>1318</fpage>&#x02013;<lpage>1324</lpage>.<pub-id pub-id-type="pmid">32989019</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo2385-cit-0020">
<string-name>
<surname>Lane</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>GP</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia</article-title>. <source>Gastroenterology</source>
<year>2010</year>; <volume>139</volume>: <fpage>1918</fpage>&#x02013;<lpage>1926</lpage>.<pub-id pub-id-type="pmid">20723544</pub-id>
</mixed-citation></ref><ref id="deo2385-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo2385-cit-0021">
<string-name>
<surname>Okagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sumiyoshi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Association of second surveillance colonoscopy findings with index and first surveillance colonoscopy results</article-title>. <source>J Dig Dis</source>
<year>2020</year>; <volume>21</volume>: <fpage>272</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">32338818</pub-id>
</mixed-citation></ref></ref-list></back></article>